Overview

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Alogliptin
Inositol
Voglibose